Company Overview and News

 
Ishara Nanayakkara resigns from Seylan Bank Board

2018-09-05 lankabusinessonline
September 5, 2018 (LBO) – Controlling shareholder of listed Sri Lankan financial giant LOLC, Ishara Nanayakkara has resigned from the Board of Directors of Seylan Bank.
SEYB

 
Former Combank CEO Jegan Durairatnam joins DFCC as an Independent Non-Executive Director

2018-08-30 lankabusinessonline
August 31, 2018 (LBO) – Former CEO of Commercial Bank (COMB) Jegan Durairatnam has been appointed to the Board of Directors of DFCC. He joins the board as an independent non-executive Director.
SEYB 55BC CBQS

 
JKH’s Gihan Cooray to Chair Nations Trust Bank

2018-08-30 lankabusinessonline
August 30, 2018 (LBO) – John Keells Holdings (JKH) Group Finance Director Gihan Cooray is set to take over as Chairman of Nations Trust Bank from December 1, 2018.
SEYB JKELF JKH 55BC CBQS NTB HNB SAMP JKEHY

 
The Finance Company (TFC) lost Rs740mn in the June quarter, deposits at Rs30bn

2018-08-16 lankabusinessonline
August 16, 2018 (LBO) – Central Bank of Sri Lanka (CBSL) registered finance company The Finance Company (TFC) reported a staggering loss for the quarter ended June 2018.
SEYB

1
Seylan Bank records 21-pct YoY growth in 1Q 2018; Profit-after-tax Rs.1,053Mn

2018-05-03 lankabusinessonline
May 3, 2018 (LBO) – Sri Lanka’s Seylan Bank has posted a profit after tax of 1,053 million rupees in first quarter of 2018.
SEYB

1
Seylan Bank reports 21-pct growth in 1Q 2018; records PAT of Rs.1,053 Mn

2018-05-03 lankabusinessonline
Seylan Bank made a steady start in 2018 by posting a Profit after Tax of Rs. 1,053 Million in Q1 despite less than ideal market conditions.
SEYB

1
Essential fuel saving tips you should know

2018-04-26 lankabusinessonline
The price of petrol and diesel are at a constant rise and it’s more important than ever to start saving fuel. Here are some essential ways you can save fuel and the burden it carries on your wallet.
SEYB

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

19h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

19h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

21h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...